Felty's syndrome: favorable response to granulocyte-macrophage colony-stimulating factor in the acute phase.
We report a case of Felty's syndrome in which infectious complications due to severe neutropenia could be overcome by short-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, 7 micrograms/kg/day s.c.). Leukocyte counts rose from 1,050/mm3 at presentation to 4,470/mm3 after 15 days of treatment. A flare-up of arthritis was not noted. Defects in granulocyte function and clinical improvement prior to leukocyte rise suggest that the beneficial effect of GM-CSF is mainly due to an improvement of granulocyte function.
Kaiser
U
U
Department of Internal Medicine, Philipps-University, Marburg, FRG.
Klausmann
M
M
Kolb
G
G
Pflüger
K H
KH
Havemann
K
K
D000208:Acute Disease; D000368:Aged; D001772:Blood Cell Count / Q000187:drug effects; D005258:Felty Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006098:Granulocytes / Q000187:drug effects; D006801:Humans; D007136:Immunoglobulins / Q000097:blood / Q000187:drug effects; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D007136:Immunoglobulins; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor